foto

Prof. dr. M.J. van de Vijver MD PhD

Position
Professor
Main activities
Patient care, Research
Specialisation
Pathology
Focus of research

 Genetic alterations and gene expression profiles of solid tumors

Key publications
  • Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR, Landscape of somatic mutations in 560 breast cancer whole-genome sequences. NATURE 2016;534 (7605):47-+ [PubMed]
  • Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ, Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women. CLIN CANCER RES 2012;18 (6):1704-1715 [PubMed]
  • Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Horlings HM, Wesseling J, van de Vijver MJ, Retrospective analysis of metastatic behaviour of breast cancer subtypes. BREAST CANCER RES TR 2015;150 (3):547-557 [PubMed]
  • Rutten MJ, Dijk F, Savci-Heijink CD, Buist MR, Kenter GG, van de Vijver MJ, Jordanova ES, HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J IMMUNOL RES 2014;2014:274584 [PubMed]
  • Stephens PJ, Tarpey PS, Davies H, van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A, Lee MTM, Shen CY, tee BTK, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SAJR, Salomon AV, Børresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR [Contributors: Karesen R, Schlichting E, Naume B, Sauer T, Ottestad L]] , The landscape of cancer genes and mutational processes in breast cancer. NATURE 2012;486 (7403):400-+ [PubMed]
All Publications
Research programmes

Genetic alterations and gene expression profiles of solid tumors

Breast cancer is presently classified based on tumor diameter, histologic type and grade, lymph node status and estrogen receptor, progesterone receptor and HER2 status. This classification has important implications for the treatment of breast cancer patients.
A more refined classification should be possible based on genetic alterations and gene expression profiles.
The genetic alterations identified in breast cancer are amplification of between 10 and 20 oncogenes and mutations in tumor suppressor genes.
We have studied the genetic alterations (with a focus on HER2 gene amplification) in breast carcinomas in relation to clinical and pathological parameters.
Gene expression profiling has led to the identification of subsets of breast cancer revealed by unsupervised and supervised classification.
We have used supervised classification to identify a 70 gene prognosis profile and clinical studies are ongoing to investigate if and how this prognosis profile can be implemented in clinical practice.
In addition, our research is aimed at identifying genetic profiles associated with response to specific therapies.
The aims of our studies are to understand the development of breast cancer at the molecular level; and to use this knowledge in treating individual breast cancer patients.
 

Faculty
Prof. dr. M.J. van de Vijver MD PhD

Postdocs
Dr. F. Dijk

PhD Students
E.J.A.H. van Beek
R. Butter MD MSc
I. Nederlof
E.C. Soer
Drs. M. van der Wel
Drs. S. Bosma (Netherlands Cancer Institute)

Others
Ing. J.B.G. Halfwerk
Drs. G.K.J. Hooijer MSc

Other research related activities
  • Staff member, Netherlands Cancer Institute
  • Member, Scientific Advisory Board, Institut Curie, Paris, France
  • Member, Scientific Advisory Board, Breakthrough Breast Cancer Research Institute, London, UK
  • Membership of advisory board / Consultant, Hoffmann La Roche Ltd
  • Chairman, Dutch Mesothelioma Panel
  • Membership of advisory board / Consultant, Merck Sharp & Dohme BV
  • Membership of advisory board / Consultant, Genomic Health
Current research funding
  • AMC
  • Biopartner, ALW-NWO
  • Europese Unie
  • KWF Kankerbestrijding
  • Life Sciences Health TKI
  • Maag, Lever, Darm Stichting
  • Nierstichting Nederland
  • N.K.I.
  • Stichting Kennisbevordering Pathologie AMC
  • TNO
  • ZonMw